

BIOSTOCK PUBLISHES AN ARTICLE AFTER PROLIGHT PUBLISHED ITS YEAR-END REPORT FOR 2025

Biostock publishes an article describing how Prolight Diagnostics is now rapidly transitioning from development to pilot production. With a European clinical multicentre study planned for 2026, Prolight is firmly setting its sights on a commercial launch in 2027.

Read the full article here: <https://biostock.se/en/2026/03/prolight-diagnostics-avslutar-2025-med-starkt-momentum/>

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

[Biostock publishes an article after Prolight published its Year-End Report for 2025](#)